Top

Published in:

01-07-2016 | Focussed Research Review

Lessons learned from cancer vaccine trials and target antigen choice

Author: Lisa H. Butterfield

Published in: Cancer Immunology, Immunotherapy | Issue 7/2016

Abstract

A wide variety of tumor antigens have been targeted in cancer immunotherapy studies. Traditionally, the focus has been on commonly overexpressed antigens shared across many patients and/or tumor types. As the field has progressed, the identity of human tumor rejection antigens has broadened. Immunologic monitoring of clinical trials has slowly elucidated candidate biomarkers of immune response and clinical response, and conversely, of immune dysfunction and suppression. We have utilized MART-1/Melan-A in our melanoma studies and observed a high frequency of immune responses and several significant clinical responses in patients vaccinated with this melanosomal protein. Alpha-fetoprotein is a shared, overexpressed tumor antigen and secreted glycoprotein that we have tested in hepatocellular cancer vaccines. Our recent studies have identified immunosuppressive and immune-skewing activities of this antigen. The choice of target antigen and its form can have unexpected effects.

Butterfield LH (2015) Cancer vaccines. BMJ 350:h988. doi:10.1136/bmj.h988 CrossRefPubMedPubMedCentral

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G et al (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33(12):1325–1333. doi:10.1200/JCO.2014.57.4244 CrossRefPubMedPubMedCentral

Finn OJ, Binder RJ, Brickner AG, Butterfield LH, Ferris RL, Kalinski P et al (2009) Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O, Seliger B (eds) Tumor-associated antigens: identification, characterization and clinical applications. Wiley-VCH Verlag, GmbH & Co., Weinheim, pp 23–43

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337. doi:10.1158/1078-0432.CCR-09-0737 CrossRefPubMed

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9(3):998–1008PubMed

Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT et al (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27(5):354–367CrossRefPubMed

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ et al (2008) Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31(3):294–309. doi:10.1097/CJI.0b013e31816a8910 CrossRefPubMedPubMedCentral

Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729–766. doi:10.1146/annurev.iy.11.040193.003501 CrossRefPubMed

Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60(3):433–442. doi:10.1007/s00262-010-0960-8 CrossRefPubMed

10.

Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T et al (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29(2):121–125CrossRefPubMed

11.

Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R et al (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4(1):17–25PubMed

12.

Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM et al (1997) Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 57(14):2865–2869PubMed

13.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB et al (1998) Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 161(10):5607–5613PubMed

14.

Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM et al (1999) Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther 6(6):523–536. doi:10.1038/sj.cgt.7700076 CrossRefPubMed

15.

Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS et al (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27(3):191–200CrossRefPubMed

16.

Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH (2006) Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177(1):712–721CrossRefPubMedPubMedCentral

17.

Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R et al (2012) Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 1(3):287–357. doi:10.4161/onci.18628 CrossRefPubMedPubMedCentral

18.

Evdokimova VN, Liu Y, Potter DM, Butterfield LH (2007) AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother 30(4):425–437. doi:10.1097/CJI.0b013e31802fd8e2 CrossRefPubMedPubMedCentral

19.

Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH (2010) Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood 116(4):575–583. doi:10.1182/blood-2009-08-240325 CrossRefPubMedPubMedCentral

20.

Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH (2012) Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology 1(4):448–457CrossRefPubMedPubMedCentral

21.

Naveh HP, Vujanovic L, Butterfield LH (2013) Cellular immunity induced by a recombinant adenovirus human dendritic cell vaccine for melanoma. J Immunother Cancer 1:19. doi:10.1186/2051-1426-1-19 CrossRefPubMedPubMedCentral

22.

Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64(17):5934–5937. doi:10.1158/0008-5472.CAN-04-1261 CrossRefPubMed

23.

Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465–4469CrossRefPubMed

24.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0 CrossRefPubMed

25.

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0 CrossRefPubMed

26.

Pardee AD, Butterfield LH (2012) Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1(1):48–55. doi:10.4161/onci.1.1.18344 CrossRefPubMedPubMedCentral

27.

Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65(6):2457–2464. doi:10.1158/0008-5472.CAN-04-3232 CrossRefPubMed

28.

Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40(3):667–676. doi:10.1002/hep.20375 CrossRefPubMed

29.

Mizejewski GJ (2002) Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2(6):709–735. doi:10.1586/14737140.2.6.709 CrossRefPubMed

30.

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13(2):153–166. doi:10.1016/j.ccr.2008.01.013 CrossRefPubMed

31.

Tomasi TB Jr (1977) Structure and function of alpha-fetoprotein. Annu Rev Med 28:453–465. doi:10.1146/annurev.me.28.020177.002321 CrossRefPubMed

32.

Mizejewski GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 226(5):377–408

33.

Cohen BL, Orn A, Gronvik KO, Gidlund M, Wigzell H, Murgita RA (1986) Suppression by alpha-fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Scand J Immunol 23(2):211–223CrossRefPubMed

34.

Yachnin S (1976) Demonstration of the inhibitory effect of human alpha-fetoprotein on in vitro transformation of human lymphocytes. Proc Natl Acad Sci USA 73(8):2857–2861CrossRefPubMedPubMedCentral

35.

Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R et al (2004) Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 173(3):1772–1778CrossRefPubMed

36.

Ritter M, Ali MY, Grimm CF, Weth R, Mohr L, Bocher WO et al (2004) Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol 41(6):999–1007. doi:10.1016/j.jhep.2004.08.013 CrossRefPubMed

37.

Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V et al (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59(13):3134–3142PubMed

38.

Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB et al (2001) T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166(8):5300–5308CrossRefPubMed

39.

Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT et al (2003) T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9(16 Pt 1):5902–5908PubMed

40.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P et al (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817–2825. doi:10.1158/1078-0432.CCR-05-2856 CrossRefPubMed

41.

Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP et al (2015) Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. J Immunother Cancer 3:32. doi:10.1186/s40425-015-0077-x CrossRefPubMedPubMedCentral

42.

Pardee AD, Shi J, Butterfield LH (2014) Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol 193(11):5723–5732. doi:10.4049/jimmunol.1400725 CrossRefPubMedPubMedCentral

43.

Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469. doi:10.1182/blood-2007-09-077438 CrossRefPubMedPubMedCentral

44.

Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 86(3):513–528. doi:10.1189/JLB.0309135 CrossRefPubMedPubMedCentral

45.

Vujanovic NL, Polimeno L, Azzarone A, Francavilla A, Chambers WH, Starzl TE et al (1995) Changes of liver-resident NK cells during liver regeneration in rats. J Immunol 154(12):6324–6338PubMed

46.

Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83(1):58–63CrossRefPubMed

47.

Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S et al (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43(6):1013–1020. doi:10.1016/j.jhep.2005.05.026 CrossRefPubMed

48.

Sha WH, Zeng XH, Min L (2014) The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma. Gut Liver 8(3):298–305. doi:10.5009/gnl.2014.8.3.298 CrossRefPubMedPubMedCentral

49.

Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3):799–807. doi:10.1002/hep.23054 CrossRefPubMed

50.

Cardoso E, Valdez G, Comini E, Matera L (1991) Effect of human alpha-fetoprotein on native and in vitro-stimulated NK activity. J Clin Lab Immunol 34(4):183–188PubMed

Title: Lessons learned from cancer vaccine trials and target antigen choice
Author: Lisa H. Butterfield
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 7/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1801-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas

Improving cancer immunotherapy with DNA methyltransferase inhibitors

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

How frequently are predicted peptides actually recognized by CD8 cells?

Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia

Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer